The historical rank and industry rank for Sunshine Biopharma's FCF Margin % or its related term are showing as below:
SBFM'
s FCF Margin % Range Over the Past 10 Years
Min: -2366.67 Med: -127.77 Max: -16.99
Current: -18.14
During the past 13 years, the highest FCF Margin % of Sunshine Biopharma was -16.99%. The lowest was -2366.67%. And the median was -127.77%.
SBFM's FCF Margin % is ranked worse than 80.38% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs SBFM: -18.14
Sunshine Biopharma FCF Margin % Related Terms
Sunshine Biopharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (SBFM) has a FCF Margin % of -26.91% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sunshine Biopharma and its competitors. According to the industry distribution chart, Sunshine Biopharma ranks #770 out of 958 companies in the Drug Manufacturers industry, placing it in the top 80.4%.
Is Sunshine Biopharma's FCF Margin % too high?
Sunshine Biopharma's current FCF Margin % is -26.91%. Based on the distribution chart, Sunshine Biopharma ranks #770 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's FCF Margin % compare to SNOA and CTTH?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #770 out of 958 companies for FCF Margin %. This places Sunshine Biopharma in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sunshine Biopharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current FCF Margin % is -26.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.10, compared to a current price of $2.16 — trading 69.6% below its estimated fair value. The current FCF Margin % is -26.91%. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current FCF Margin % is -26.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Biopharma (SBFM) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued.
The current stock price of $2.16 is trading 69.6% below its estimated GF Value™ of $7.10.
GuruFocus considers Sunshine Biopharma to be Possible Value Trap.
Key valuation signals for SBFM:
FCF Margin %: -26.91%
GF Value™: $7.10 vs. price of $2.16 (69.6% below fair value)
No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFM has been successfully added to your 
